65
Participants
Start Date
May 7, 2021
Primary Completion Date
March 30, 2023
Study Completion Date
March 30, 2023
VBR
VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
AB-729
AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
SOC NrtI
Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Auckland Clinical Studies, Auckland
Acibadem City Clinic Tokuda Hospital, Sofia
Diagnostic Consultative Center Aleksandrovska, Sofia
University Multiprofile Hospital for Active Treatment St. Ivan Rilski, Sofia
Saint Vincent's Hospital Sydney, Darlinghurst
Westmead Hospital, Westmead
Liverpool Hospital, Liverpool
Saint George Hospital - Australia, Kogarah
The Alfred Hospital, Melbourne
Footscray Hospital, Footscray
Melbourne Health, Parkville
Nov Rehabilitatsionen Tsentar EOOD, Stara Zagora
Sir Charles Gairdner Hospital, Nedlands
Wellington Regional Hospital, Wellington
Vancouver Infectious Disease Centre, Vancouver
Pacific Gastroenterology Associates, Vancouver
University Hospital - London Health Sciences Centre, London
Ottawa Hospital Research Institute, Ottawa
Toronto Liver Centre, Toronto
Centre Hospitalier Université de Québec - Université Laval, Québec
Lead Sponsor
Collaborators (1)
Arbutus Biopharma Corporation
INDUSTRY
Assembly Biosciences
INDUSTRY